drugset / Trial / NCT07514429
Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial
Phase 2
Not yet recruiting
24 enrolled
Ju Hyun Shim
Boryung Pharmaceutical Co., Ltd · collabHanyang University Guri Hospital · collabNational Cancer Center, Korea · collabSamsung Medical Center · collabSeoul National University Bundang Hospital · collabSeoul National University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of regorafenib as a subsequent therapy for patients with hepatocellular carcinoma (HCC) who have failed prior lenvatinib treatment. This investigational study aims to assess the therapeutic benefits and safety profile of regorafenib in patients whose disease has progressed following the use of lenvatinib, a targeted therapy for hepatocellular carcinoma
Timeline
- Start
- 2026-03-15
- Primary completion
- 2028-05-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 120 mg | Oral |
| Subject | Regorafenib | Small molecule | 160 mg | Oral |